From class waivers to precision medicine in paediatric oncology

Andrew D.J. Pearson, Stefan M. Pfister, Andre Baruchel, Jean Pierre Bourquin, Michela Casanova, Louis Chesler, François Doz, Angelika Eggert, Birgit Geoerger, David T.W. Jones, Pamela R. Kearns, Jan J. Molenaar, Bruce Morland, Gudrun Schleiermacher, Johannes H. Schulte, Josef Vormoor, Lynley V. Marshall, C. Michel Zwaan, Gilles Vassal, Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium

Research output: Contribution to journalReview article

Abstract

New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively searched oncology drugs that were class waivered between June, 2012, and June, 2015. 147 oncology class waivers were confirmed for 89 drugs. Mechanisms of action were then assessed as potential paediatric therapeutic targets by both a literature search and an expert review. 48 (54%) of the 89 class-waivered drugs had a mechanisms of action warranting paediatric development. Two (2%) class-waivered drugs were considered not relevant and 16 (18%) required further data. In light of these results, we propose five initiatives: an aggregated database of paediatric biological tumour drug targets; molecular profiling of all paediatric tumours at diagnosis and relapse; a joint academic–pharmaceutical industry preclinical platform to help analyse the activity of new drugs (Innovative Therapy for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform); paediatric strategy forums; and the suppression of article 11b of the European Paediatric Regulation, which allows product-specific waivers on the grounds that the associated condition does not occur in children. These initiatives and a mechanism of action-based approach to drug development will accelerate the delivery of new therapeutic drugs for front-line therapy for those children who have unmet medical needs.

Original languageEnglish
Pages (from-to)e394-e404
JournalThe Lancet Oncology
Volume18
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Precision Medicine
Pediatrics
Pharmaceutical Preparations
Neoplasms
Investigational Therapies
Industry
Therapeutics
Joints
Databases
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Pearson, A. D. J., Pfister, S. M., Baruchel, A., Bourquin, J. P., Casanova, M., Chesler, L., ... Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium (2017). From class waivers to precision medicine in paediatric oncology. The Lancet Oncology, 18(7), e394-e404. https://doi.org/10.1016/S1470-2045(17)30442-4

From class waivers to precision medicine in paediatric oncology. / Pearson, Andrew D.J.; Pfister, Stefan M.; Baruchel, Andre; Bourquin, Jean Pierre; Casanova, Michela; Chesler, Louis; Doz, François; Eggert, Angelika; Geoerger, Birgit; Jones, David T.W.; Kearns, Pamela R.; Molenaar, Jan J.; Morland, Bruce; Schleiermacher, Gudrun; Schulte, Johannes H.; Vormoor, Josef; Marshall, Lynley V.; Zwaan, C. Michel; Vassal, Gilles; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium.

In: The Lancet Oncology, Vol. 18, No. 7, 01.07.2017, p. e394-e404.

Research output: Contribution to journalReview article

Pearson, ADJ, Pfister, SM, Baruchel, A, Bourquin, JP, Casanova, M, Chesler, L, Doz, F, Eggert, A, Geoerger, B, Jones, DTW, Kearns, PR, Molenaar, JJ, Morland, B, Schleiermacher, G, Schulte, JH, Vormoor, J, Marshall, LV, Zwaan, CM, Vassal, G & Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium 2017, 'From class waivers to precision medicine in paediatric oncology', The Lancet Oncology, vol. 18, no. 7, pp. e394-e404. https://doi.org/10.1016/S1470-2045(17)30442-4
Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L et al. From class waivers to precision medicine in paediatric oncology. The Lancet Oncology. 2017 Jul 1;18(7):e394-e404. https://doi.org/10.1016/S1470-2045(17)30442-4
Pearson, Andrew D.J. ; Pfister, Stefan M. ; Baruchel, Andre ; Bourquin, Jean Pierre ; Casanova, Michela ; Chesler, Louis ; Doz, François ; Eggert, Angelika ; Geoerger, Birgit ; Jones, David T.W. ; Kearns, Pamela R. ; Molenaar, Jan J. ; Morland, Bruce ; Schleiermacher, Gudrun ; Schulte, Johannes H. ; Vormoor, Josef ; Marshall, Lynley V. ; Zwaan, C. Michel ; Vassal, Gilles ; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium. / From class waivers to precision medicine in paediatric oncology. In: The Lancet Oncology. 2017 ; Vol. 18, No. 7. pp. e394-e404.
@article{f42c3184d13f4d7aa02781d113ea137b,
title = "From class waivers to precision medicine in paediatric oncology",
abstract = "New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively searched oncology drugs that were class waivered between June, 2012, and June, 2015. 147 oncology class waivers were confirmed for 89 drugs. Mechanisms of action were then assessed as potential paediatric therapeutic targets by both a literature search and an expert review. 48 (54{\%}) of the 89 class-waivered drugs had a mechanisms of action warranting paediatric development. Two (2{\%}) class-waivered drugs were considered not relevant and 16 (18{\%}) required further data. In light of these results, we propose five initiatives: an aggregated database of paediatric biological tumour drug targets; molecular profiling of all paediatric tumours at diagnosis and relapse; a joint academic–pharmaceutical industry preclinical platform to help analyse the activity of new drugs (Innovative Therapy for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform); paediatric strategy forums; and the suppression of article 11b of the European Paediatric Regulation, which allows product-specific waivers on the grounds that the associated condition does not occur in children. These initiatives and a mechanism of action-based approach to drug development will accelerate the delivery of new therapeutic drugs for front-line therapy for those children who have unmet medical needs.",
author = "Pearson, {Andrew D.J.} and Pfister, {Stefan M.} and Andre Baruchel and Bourquin, {Jean Pierre} and Michela Casanova and Louis Chesler and Fran{\cc}ois Doz and Angelika Eggert and Birgit Geoerger and Jones, {David T.W.} and Kearns, {Pamela R.} and Molenaar, {Jan J.} and Bruce Morland and Gudrun Schleiermacher and Schulte, {Johannes H.} and Josef Vormoor and Marshall, {Lynley V.} and Zwaan, {C. Michel} and Gilles Vassal and {Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/S1470-2045(17)30442-4",
language = "English",
volume = "18",
pages = "e394--e404",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "7",

}

TY - JOUR

T1 - From class waivers to precision medicine in paediatric oncology

AU - Pearson, Andrew D.J.

AU - Pfister, Stefan M.

AU - Baruchel, Andre

AU - Bourquin, Jean Pierre

AU - Casanova, Michela

AU - Chesler, Louis

AU - Doz, François

AU - Eggert, Angelika

AU - Geoerger, Birgit

AU - Jones, David T.W.

AU - Kearns, Pamela R.

AU - Molenaar, Jan J.

AU - Morland, Bruce

AU - Schleiermacher, Gudrun

AU - Schulte, Johannes H.

AU - Vormoor, Josef

AU - Marshall, Lynley V.

AU - Zwaan, C. Michel

AU - Vassal, Gilles

AU - Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium

PY - 2017/7/1

Y1 - 2017/7/1

N2 - New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively searched oncology drugs that were class waivered between June, 2012, and June, 2015. 147 oncology class waivers were confirmed for 89 drugs. Mechanisms of action were then assessed as potential paediatric therapeutic targets by both a literature search and an expert review. 48 (54%) of the 89 class-waivered drugs had a mechanisms of action warranting paediatric development. Two (2%) class-waivered drugs were considered not relevant and 16 (18%) required further data. In light of these results, we propose five initiatives: an aggregated database of paediatric biological tumour drug targets; molecular profiling of all paediatric tumours at diagnosis and relapse; a joint academic–pharmaceutical industry preclinical platform to help analyse the activity of new drugs (Innovative Therapy for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform); paediatric strategy forums; and the suppression of article 11b of the European Paediatric Regulation, which allows product-specific waivers on the grounds that the associated condition does not occur in children. These initiatives and a mechanism of action-based approach to drug development will accelerate the delivery of new therapeutic drugs for front-line therapy for those children who have unmet medical needs.

AB - New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively searched oncology drugs that were class waivered between June, 2012, and June, 2015. 147 oncology class waivers were confirmed for 89 drugs. Mechanisms of action were then assessed as potential paediatric therapeutic targets by both a literature search and an expert review. 48 (54%) of the 89 class-waivered drugs had a mechanisms of action warranting paediatric development. Two (2%) class-waivered drugs were considered not relevant and 16 (18%) required further data. In light of these results, we propose five initiatives: an aggregated database of paediatric biological tumour drug targets; molecular profiling of all paediatric tumours at diagnosis and relapse; a joint academic–pharmaceutical industry preclinical platform to help analyse the activity of new drugs (Innovative Therapy for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform); paediatric strategy forums; and the suppression of article 11b of the European Paediatric Regulation, which allows product-specific waivers on the grounds that the associated condition does not occur in children. These initiatives and a mechanism of action-based approach to drug development will accelerate the delivery of new therapeutic drugs for front-line therapy for those children who have unmet medical needs.

UR - http://www.scopus.com/inward/record.url?scp=85028073306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028073306&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(17)30442-4

DO - 10.1016/S1470-2045(17)30442-4

M3 - Review article

C2 - 28677575

AN - SCOPUS:85028073306

VL - 18

SP - e394-e404

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -